Home › MannKind's Afrezza Remains in Sanofi's Plans, RBC Says
 

Keywords :   


MannKind's Afrezza Remains in Sanofi's Plans, RBC Says

2014-11-22 19:25:26| Biotech - Topix.net

Yesterday, Sanofi hosted a seminar on new medicines in Cambridge, Mass., and RBC's Adnan Butt and team note that MannKind's inhaled insulin Afrezza "featured prominently enough." They summarize the highlights of the presentation: MannKind's partner reiterated prior guidance that a commercial launch is planned for 1Q:15.

Tags: plans says remains rbc

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Kim Madigan to chair 2025 FTA Fall Technical Conference
05.11PM responds to Sir Alan Bates after repeated requests
05.11American Angus elects 2024-25 board leaders
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 8A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
More »